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Abstract
Introduction: Previous studies showed that higher testosterone levels are associated with greater risk of breast
cancer in premenopausal women, but the literature is scant and inconsistent.
Methods: In a prospective nested case-control study of 104 premenopausal women with incident breast cancer
and 225 matched controls, all characterized by regular menstrual cycles throughout their lifetime, we measured the
concentration of estradiol, total and free testosterone (FT), progesterone, sex hormone-binding globulin (SHBG),
follicle-stimulating hormone (FSH), and luteinizing hormone (LH) in blood samples collected on days 20 through 24
of their cycles.
Results: In logistic regression models, the multivariate odds ratios (ORs) of invasive breast cancer for women in the
highest tertile of circulating FT compared with the lowest was 2.43 (95% confidence interval (95% CI), 1.15 to 5.10;
Ptrend = 0.03), whereas for total testosterone, the association had the same direction but was not statistically
significant (OR, 1.27; 95% CI, 0.62 to 2.61; Ptrend = 0.51). Endogenous progesterone was not statistically associated
with breast cancer (OR, 1.16; 95% CI, 0.60 to 2.27; Ptrend = 0.75), nor were the other considered hormones.
Conclusions: Consistent with previous prospective studies in premenopausal women and our own earlier
investigation, we observed that higher levels of FT are positively associated with breast cancer risk in women with
regular menstrual cycles throughout their lifetimes. No evidence of risk was found associated with the other
endogenous sex steroids.
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Introduction
Sex steroids regulate cell proliferation and play a major
role in breast cancer promotion [1,2]. Particularly andro-
gens and estrogens have been associated with breast
cancer risk in postmenopausal women [3]. Few previous
studies have evaluated the association between circulating
sex steroids and breast cancer risk in premenopausal
women, and in general, they [4-16] do suggest a consistent
association with breast cancer risk only for total and bioa-
vailable testosterone, whereas the role of estradiol and pro-
gesterone has been less clear and inconsistent, thus far [1].
These studies, however, tended to be limited by intraindi-
vidual hormone variability due to the ovarian cycle and by
technical variability in hormone assays. We sought to clar-
ify further the strength of the association between prediag-
nostic sex steroid hormones and breast cancer incidence
in premenopausal women. The prospective nature of our
study, careful control of hormone variability through both
a specifically developed study design and highly standar-
dized protocols for specimen collection and storage, avail-
ability of stored biologic samples, and detailed information
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pometric measurements, together with a median cohort
follow-up of 20 years and the identification of all breast
cancer cases assured by the local Varese Cancer Registry,
render the Hormones and Diet in the Etiology of Breast
Cancer Risk (ORDET) study an ideal setting for better
clarification of hormonal risk factors in relation to breast
cancer development [17-19].
This current analysis is based on a substantial update of
a previous analysis [12], which used only roughly one fifth
of all women with breast cancer that constitute the current
sample. We evaluated associations between mid-luteal
total and free testosterone (FT), estradiol, progesterone,
and sex hormone-binding globulin (SHBG) and premeno-
pausal breast cancer risk. We also considered in the analy-
sis follicle-stimulating hormone (FSH) and luteinizing
hormone (LH).
Methods
The ORDET cohort was established in northern Italy
between June 1987 and June 1992, when 10,786 healthy
women, ages 35 to 69 years, were enrolled [20,21].
They were all residents of the Varese province, an area
covered by the Varese Cancer Registry [22], who had
heard about the study through the media, at public meet-
ings, and at breast cancer early-detection centers, and who
volunteered to participate. At recruitment, a number of
baseline characteristics, including demographics and diet-
ary intake, were queried from each participant via ques-
tionnaire. Direct measurements of several anthropometric
variables, including height and weight, were conducted,
and blood and urine specimens were collected. Because of
the focus of the study on endogenous hormones and their
relation with breast cancer risk, stringent inclusion criteria
were established, and highly standardized conditions on
collecting biologic samples were applied. Women were
excluded if they reported a bilateral oophorectomy, were
currently breast feeding or pregnant, used oral contracep-
tives or hormone-replacement therapy in the last
3 months, were affected by chronic or acute liver disease,
or reported a history of cancer (with the exception of non-
melanoma skin cancer).
Information on cancer outcomes, which was available
from the local cancer registry (Varese Cancer Registry),
was linked to the ORDET cohort to identify incident breast
cancer cases up to December 2003. The Varese Cancer
Registry is of high quality: <2% of breast cancer cases are
known to the registry by death certificate only, and the his-
tology and cytology of 96.3% of all cases has been con-
firmed through pathology reports [20,23]. The ORDET file
was also linked to the Varese residents’ files to check parti-
cipants’ vital status. Participants were censored at the time
of cancer diagnosis, death, or loss to follow-up, whichever
came first (median follow-up time, 15.4 years). Written
consent was obtained from all study participants, and the
study was approved by the Ethical Review Board of the
National Cancer Institute of Milan (Italy).
Assessment of menopausal status and selection of
study subjects
Case subjects were women who developed breast cancer
after their recruitment into the ORDET cohort but
before the end of the study period (December 31, 2003).
For each case subject with breast cancer, up to four
control subjects were randomly chosen from appropriate
risk sets consisting of all cohort members who satisfied
the matching criteria and were alive and free of cancer
at the time of diagnosis of the index case. Matching
characteristics were age (±3 years) at enrollment and
date of recruitment (±180 days). Once each breast can-
cer case was matched with her controls, to reduce the
interbatch technical variability, we assessed their hormo-
nal levels within the same laboratory batch. An inci-
dence density-sampling protocol for control selection
was used, such that controls could include a subject
who became a case later, whereas each control subject
could also be sampled more than once.
After exclusion of women with a history of cancer and
women who, immediately after baseline, were lost to fol-
low-up (observed time = 0), 10,633 participants remained
to form the base population of ORDET. For this study,
we further restricted the ORDET cohort to its 6,667 pre-
menopausal participants. Women were classified as pre-
menopausal, at recruitment, if they had at least one
menstruation in the 6 months before recruitment. All
breast cancer cases were premenopausal at blood draw.
To define premenopause more stringently, only women
with FSH levels <30 μl/ml were initially included (205
cases and 767 controls). Of these 205 cases, 20 had in
situ breast cancer. We conducted separated analyses
including and excluding the 20 breast cancers in situ.
The results were similar, and we decided to describe the
study results with the inclusion of the breast cancer
in situ.
In addition, to control by study design the biologic
variability due to irregular ovarian cycles, we considered
only cases and control women who reported menstrual
cycles at fairly regular intervals throughout their life
(126 breast cancer cases and 474 control subjects) and
excluded women with marked menstrual irregularities
(that is, women with more than one period missing in a
6-month period: 79 breast cancer cases and matched
293 control subjects) and women who had the men-
strual cycle at blood collection longer than 45 days (13
breast cancer cases and 49 matched controls). These
restrictions left nine cases without matched controls and
200 controls without matched cases, hence 104 case
women and 225 controls were included in this study.
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A detailed description of blood-collection methods was
provided previously [12,17]. In brief, blood samples were
collected after overnight fasting between 7:30 AM and
9:00 AM from each woman. They were timed to be col-
lected between days 20 and 24 of their menstrual cycle
(that is, during the midluteal phase). For further verifica-
tion of their luteal phase during blood collection, women
were given a postcard to report the date of the subse-
quent bleeding after the blood drawing. Of 6,667 women
who had at least one menstruation in the 12 months
before recruitment, 6,030 (90.4%) returned their postcard
with information on the date of the menses subsequent
to the blood collection. Blood samples were stored at
-80°C until the present hormone determinations.
Laboratory methods
Stability and reliability of the ORDET collection method
for sex steroids in premenopausal women were previously
described [12]. Blood samples from breast cancer cases
and related controls were handled identically and assayed
together on the same day and in the same run. All samples
were taken out of the freezer simultaneously and sent to
the laboratory in the same parcel on dry ice. Laboratory
personnel were blinded to case-control status. Control of
analytic error was based on the inclusion of two standard
samples.
All samples were assayed in duplicate, by using commer-
cially available kits following the manufacturer’si n s t r u c -
tions. Plasma sex steroid measurements (testosterone, free
testosterone, SHBG, and estradiol) were conducted by
Centro Medico Diagnostico Emilia (Bologna, Italy). For
testosterone and free testosterone, we used Coat-A-Count
procedure, a solid-phase radioimmunoassay (Diagnostic
Products Corporation, Los Angeles, CA, USA); for SHGB,
IMMUNOLITE 1000 Analyzer, a solid-phase, chemilumi-
nescent immunometric assay (Diagnostic Products); and
for estradiol, Orion Diagnostica SPECTRIA Estradiol
Sensitive RIA test, a coated-tube radioimmunoassay
(Orion Diagnostica Oy, Espoo, Finland). Quality control
was done at three concentrations for SHBG and total and
free testosterone and at four concentrations for total estra-
diol. In each batch, quality-control samples were evaluated
in quadruplicate. Within-batch quality control coefficients
of variation for high and low concentrations were 5.9%
and 14.0% for estradiol; 5.8% and 10.6% for total testoster-
one; 7.0% and 9.6% for free testosterone; and 3.1% and
3.4% for SHBG. Average between-batch coefficients of var-
iation for high and low concentrations were 7.4% and
16.4% for estradiol, 8.7% and 18.5% for total testosterone,
14.9% and 17.2% for free testosterone, and 4.9% and 4.6%
for SHBG. Serum levels of progesterone were compatible
with ovulatory cycles, ranging between 5.3 and 21.5 ng/ml
in control subjects and between 4.8 and 20.8 ng/ml in inci-
dent breast cancer cases.
Statistical analyses
Based on their distribution, we applied logarithmic
transformations to the data for LH, FSH, and SHBG,
and square-root transformations to total testosterone,
free testosterone, progesterone, and estradiol. We evalu-
ated differences between case and control means by
using the t test for paired data or the Wilcoxon signed
test, as appropriate. Pearson partial correlation coeffi-
cients, adjusted for age and case-control status, were
computed to examine the strength of linear associations
among the various hormones and between each hor-
mone, the waist circumference, and the body mass
index (BMI).
We used conditional regression models to estimate the
relative risks of breast cancer (reported as odds ratios
(ORs) with 95% confidence inter v a l s( C I s ) )b yt e r t i l e so f
circulating sex steroids, which were defined on the basis of
the values for all control subjects. We used likelihood ratio
tests to assess linear trends in odds ratios, with increasing
exposure level as a continuous variable.
The effects of additional potential confounders (other
than the matching criteria, which were controlled by study
design) were examined by including additional regression
terms into the logistic regression models. Potential con-
founders included age at recruitment, BMI, because of its
role in the hormone metabolism, education, and years of
education. Furthermore, the better to characterize the per-
iod of the ovarian cycle at blood drawing (12), multivariate
models were adjusted for variables related to the timing of
the ovarian cycle at blood drawing, such as time between
date of last menses before blood sampling and day of
blood sampling, time between date of menses after blood
sampling and date of blood sampling, circulating FSH and
LH levels, and menstrual-cycle length. We used STATA
version 8 for all analyses. All P values were two-sided.
Results
Study participants were all premenopausal, with an age
range of 35 to 54 years at blood collection. Most of the
women’s baseline characteristics did not differ by case-
control status (Table 1), in particular, for the reproduc-
tive variables.
In Table 2 partial correlation coefficients, adjusted for
case-control status and age at blood donation, indicated
that serum concentration of estradiol (E2) statistically
significantly correlated with all the other hormones,
with correlation coefficients (r) ranging from 0.20 with
progesterone to 0.38 with total testosterone. Also, the
sex hormone-binding globulin (SHBG) statistically sig-
nificantly correlated with most of hormones, with the
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also observed that SHBG had significant negative corre-
lation with BMI (r = -0.25), waist-to-hip ratio (r =
-0.21), FSH (r = -0.12), and free testosterone (r = -0.22).
Both total testosterone and free testosterone correlated
with estradiol (free testosterone, r = 0.22) and LH (r =
0.22 and r = 0.11 for total and free testosterone, respec-
tively). In addition, free testosterone correlated with BMI
(r = 0.16). For all study subjects combined, women who
developed breast cancer had statistically significantly
higher mean levels of free testosterone. Specifically, we
observed a significant association for circulating free tes-
tosterone (OR for highest versus lowest tertile, 2.43; 95%
CI, 1.15 to 5.10; Ptrend = 0.03; Table 3).
We also observed a positive albeit nonsignificant asso-
ciation for circulating total testosterone (OR for highest
versus lowest tertile, 1.27; 95% CI, 0.62 to 2.61; Ptrend =
0.51). Further, none of the other sex steroids evaluated
showed significant associations with breast cancer risk in
this data set. We examined the effects of various confoun-
ders on these relative-risk estimates by performing
adjusted analyses. Relative-risk estimates remained vir-
tually unchanged after adjustments for BMI and educa-
tion. We also evaluated potential variation in the risk
estimates for free testosterone by adjusting in different
models for progesterone, total testosterone, estradiol, and
SHBG, and by excluding breast cancer cases diagnosed
Table 1 Descriptive characteristics of 104 premenopausal women with invasive (n = 88) or in situ (n = 10) breast
cancer and 225 matched controls; baseline values
Mean or median difference Student t
Cases Controls 95% IC P value
Age, year; mean (SD) 43.5 (4.3) 43.3 (4.0) -0.06 - 0.46 0.134
Age at menarche, year;
median (interquartile range)
13 (12;14) 12.5 (12;13.3) -1.0 - 0.0 0.723
a
Parity (parous women only); median (interquartile range) 2 (1.0;2.0) 2 (1.1;2.3) -0.25 - 0.25 0.640
a
Age at first birth (parous women only); median (rnterquartile range) 24.8 (22.3;28.3) 24.3 (21.8;26.1) -2.79 - 0.69 0.229
a
BMI, kg/m
2; mean (SD) 25.0 (4.5) 25.2 (3.4) -1.28 - 0.91 0.733
Alcohol consumption, g/d;
mean (SD)
1.7 (1.3) 1.5 (1.1) -0.25 - 0.70 0.346
Pack-years, ever smokers; mean (SD) 7.8 (5.9) 10.2 (10.0) -6.48 - 1.64 0.230
c
2
P value
Breastfeeding; n (%) 73 (70.2) 166 (73.8) 0.354
OC use; n (%) 43 (41.3) 92 (40.9) 0.350
Education beyond 8 years
of elementary school; n (%)
68 (65.4) 119 (52.9) 0.001
Current smoker; n (%) 22 (21.2) 44 (19.6) 0.387
Past smoker; n (%) 19 (18.3) 24 (10.7) 0.019
Never smoker; n (%) 63 (60.6) 157 (69.8) 0.860
BMI, body mass index; OC, oral contraceptive.
aWilcoxon test.
Table 2 Partial correlation coefficients adjusted for case-control status and age at the blood donation
(104 premenopausal breast cancer cases and 225 matched controls)
SHBG nmol/ml TT ng/ml FT
pg/ml
PG ng/ml E2
pg/ml
FSH mIU/ml LH mIU/ml BMI Waist circumference
SHBG nmol/ml 1
TT ng/ml 0.131
a 1
FT pg/ml -0.225
b 0.582
b 1
PG ng/ml 0.190
b -0.019 -0.001 1
E2 pg/ml 0.323
b 0.378
b 0.221
b 0.197
b 1
FSH mIU/ml -0.118
a -0.024 -0.058 -0.348
b -0.257
b 1
LH mIU/ml -0.064 0.216
b 0.115
a -0.283
b 0.122
a 0.668
b 1
BMI -0.253
b 0.066 0.162
b -0.097 -0.029 0.024 -0.006 1
Waist circumference -0.211
b 0.043 0.105 -0.080 -0.101 0.025 -0.008 0.842
b 1
aThe correlation is significant at the 0.05 level (two-tailed).
bThe correlation is significant at the 0.01 level (two-tailed).
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risk estimates remained very similar (data not shown).
Discussion
This study was designed to provide information on breast
cancer risk in relation to serum levels of sex hormones
that markedly vary over the menstrual cycle. To reduce
this variability, blood samples were collected within a nar-
row window (days 20 to 24 of the cycle) when most
women were in midluteal phase. Then we adjusted our
estimates for variables related to ovarian-cycle time inter-
vals and restricted the analyses to women with regular
cycles throughout their life.
Our findings are largely in line with those of previous
reports, which have found few consistent associations
between sex steroids and breast cancer risk in premeno-
pausal women, with the exception of the consistent risk
elevation associated with testosterone and free testoster-
one. Of the prospective studies published to date [4-16],
the two largest ones, based in the European Prospective
Investigation into Cancer and Nutrition (EPIC) and
Nurses’ Health Study II (NHS2) cohorts, reported for cir-
culating estradiol either no overall association [4] or only
if estradiol levels were measured in the follicular phase of
the menstrual cycle [11]. Our blood samples were col-
lected exclusively in the luteal phase of the menstrual
cycle, and even though we accounted for the exact day
within a woman’s menstrual cycle at which blood was
drawn, we did not observe an association between luteal
circulating estradiol and breast cancer risk in our analyses,
which is in line with the findings from the NHS cohorts
[11]. For progesterone, previous reports were conflicting,
reporting no [11] or a significant inverse association [4]
with breast cancer risk. Similarly, few and mostly small
prospective studies have explored the association between
circulating testosterone and premenopausal breast cancer
risk. Both the European Prospective Investigation into
Cancer (EPIC) and Nurses’ Health Study (NHS) cohorts
[4,11], the two largest studies to date, report positive asso-
ciations, particularly if testosterone was measured in the
luteal phase [11]. We, too, observed a significantly in-
creased risk of breast cancer associated with higher circu-
lating levels of free testosterone. We did not observe an
association between SHBG and breast cancer risk in our
study, which is also consistent with prior evidence
[4,8,9,11,12].
Our study has several important strengths, relating to its
prospective nature and carefully timed sample collection,
as well as information on important confounders. This
study is unique in that we were able to collect information
on a women’s history of menstrual-cycle irregularities
throughout life, which allowed us subsequently to restrict
it to women with very consistent hormone profiles over
their entire reproductive period. Our results support that,
in premenopausal women, it is imperative to apply a strict
control of the biologic variability of hormones and/or
other biologic variables to test potential associations with
specific outcomes. In our sensitivity analyses, excluding
cases diagnosed within 2 years after blood collection, or
in situ breast cancers, did not alter our findings.
Our study is limited by its relatively small sample size
(even though it still ranks among the larger studies pub-
lished), which precluded more-detailed stratified analyses.
Whether a single blood measurement of sex steroid hor-
mones, which fluctuate during the menstrual cycle, suffi-
ciently characterizes a premenopausal woman’s long-term
hormone levels is another concern. However, previous stu-
dies showed, particularly for androgens, estrone sulfate,
and to a lesser degree for estradiol and progesterone, that
Table 3 Relative risk (OR) of breast cancer among 104
premenopausal case women with regular menstrual
cycles throughout their lives and whose last cycle did
not exceed 45 days, and their 225 matched controls, by
tertiles of sex steroids
a
Tertiles Cases/Controls Crude OR
a
(95% CI)
Adjusted OR
b
(95% CI)
Estradiol (pg/ml)
1 42/75 1.00 (Reference) 1.00 (Reference)
2 30/75 0.67 (0.38-1.18) 0.62 (0.34-1.15)
3 32/75 0.71 (0.39-1.27) 0.69 (0.35-1.35)
P for trend 0.21 0.25
Progesterone (ng/ml)
1 32/75 1.00 (Reference) 1.00 (Reference)
2 42/75 1.19 (0.69-2.06) 1.56 (0.83-2.97)
3 30/75 0.92 (0.50-1.69) 1.16 (0.60-2.27)
P for trend 0.81 0.75
Total testosterone (ng/ml)
1 33/75 1.00 (Reference) 1.00 (Reference)
2 37/80 1.03 (0.56-1.90) 1.07 (0.56-2.04)
3 34/70 1.11 (0.58-2.14) 1.27 (0.62-2.61)
P for trend 0.75 0.51
Free testosterone (pg/ml)
1 20/75 1.00 (Reference) 1.00 (Reference)
2 41/75 2.30 (1.15-4.58) 2.31 (1.12-4.76)
3 43/75 2.20 (1.12-4.32) 2.43 (1.15-5.10)
P for trend 0.03 0.03
SHBG (mmol/ml)
1 41/75 1.00 (Reference) 1.00 (Reference)
2 29/77 0.68 (0.38-1.21) 0.66 (0.36-1.21)
3 34/73 0.86 (0.48-1.55) 0.93 (0.50-1.72)
P for trend 0.60 0.78
aOR and Wald 95% CI based on conditional logistic regression models (matching
factors: age (±3 years) at enrollment, date of recruitment (±180 days), and
laboratory batch).
bFurther adjusted for age at recruitment, BMI, time between
date of last menses before blood sampling and day of blood sampling; time
between date of menses after blood sampling and date of blood sampling;
circulating FSH and LH levels, and menstrual cycle length. BMI, body mass index;
95% CI, 95% confidence interval; FSH, follicle-stimulating hormone; LH, luteinizing
hormone; OR, odds ratio; SHBG, sex hormone-binding globulin.
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over at least a 3-year period in premenopausal women
[24]. Nonetheless, the necessity to better characterize and
measure the exposure to serum hormones called for a
careful assessment of menstrual-cycle variability. We
excluded these women from our dataset, reducing sample
size but substantially improving our ability to detect asso-
ciations that appear to become apparent only when bio-
logic variability is controlled for. In our analyses, no
mathematical correction was made for multiple compari-
sons. However, although such correction would have
diminished significance (for example, after Bonferroni cor-
rection, Ptrend < 0.01 would be considered statistically sig-
nificant, and none of our P values met this threshold), it
does not appear to be needed, given that we conducted
only a few scientifically sensible comparisons.
Conclusions
Our findings suggest that premenopausal circulating tes-
tosterone, particularly free testosterone, is associated
with breast cancer risk when ovarian-cycle variability is
carefully controlled for. We also show that other sex
steroids do not appear to play a major role in develop-
ing premenopausal breast cancer. As evidence continues
to accumulate for a positive association between preme-
nopausal circulating testosterone and breast cancer risk,
potential new preventive strategies should be designed
and tested.
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